After several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for its ovarian cancer drug Lynparza in the US and the first approval in China for its new anemia drug. While AZ’s immunotherapy drug Imfinzi has made some missteps recently, most notably in first-line lung cancer, its well-established poly (ADP-ribose) polymerase (PARP) class drug Lynparza has gone from strength to strength. AZ is developing Lynparza with Merck & Co, and the FDA ha...
READ MORE
|
French drugmaker Sanofi announced Wednesday that it is leveraging the data analytics platform of New York-based Aetion to gather real-world evidence that can advance its understanding of the effectiveness, safety, and value of drugs. Specifically, Aetion’s platform will be integrated with Sanofi’s real-world data platform called Darwin. Per the announcement of this collaboration and company-wide integration, Sanofi’s DARWIN compiles and analyzes de-identified data from hundreds...
READ MORE
|
Reporters obtained the following quote from the background information supplied by the inventors: "This disclosure relates generally to methods and devices for use in treating various ocular diseases. Glaucoma is caused by a number of different eye diseases which can produce increased intraocular pressure (IOP) in the eye. The increased pressure is often caused by a backup of aqueous humour within the eye. Over time, the increased pressure can cause damage to the optic nerve, which can lead to b...
READ MORE
|
Uveal melanoma is a very aggressive type of melanoma that affects the eye. It is a rare disorder, affecting an estimated 2,500 people in the United States each year. However, nearly half of uveal melanoma patients will develop metastatic disease that migrates to other part of the body, primarily the liver. The prognosis for patients with metastatic uveal melanoma is very poor, with median survival of only 17 to 20 months. Researchers in Moffitt Cancer Center's Donald A. Adam Melanoma and Ski...
READ MORE
|
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids....
READ MORE
|
Sanofi and Regeneron Pharmaceuticals’ drug Kevzara (sarilumab) has received the US Food and Drug Administration (FDA) approval to treat adult patients affected with moderately to severely active rheumatoid arthritis (RA)....
READ MORE
|